预约演示
更新于：2025-09-09
Phenylephrine Hydrochloride
盐酸去氧肾上腺素
更新于：2025-09-09
概要
基本信息
简介苯肾上腺素是一种小分子药物，其作用为α-1肾上腺素能受体激动剂。它主要用于扩张眼瞳以进行眼科检查和手术。通过与虹膜扩张肌中的α-1肾上腺素受体结合，苯肾上腺素盐酸盐引起肌肉收缩，导致瞳孔扩张。这种药物通常用于眼科诊断，例如检查视网膜或测量眼内压。苯肾上腺素盐酸盐以滴眼剂的形式局部给药，通常在10到20分钟内起效，扩张效果可持续数小时 |
药物类型 小分子化药 |
别名 (-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol、fenilefrine、l-(3-Hydroxyphenyl)-N-methylethanolamine + [22] |
靶点 |
作用方式 激动剂 |
作用机制 ADRA1激动剂(肾上腺素能受体α-1家族激动剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C9H14ClNO2 |
InChIKeyOCYSGIYOVXAGKQ-FVGYRXGTSA-N |
CAS号61-76-7 |
关联
374
项与 盐酸去氧肾上腺素 相关的临床试验NCT06648850
Clinical Study of DA-001 as a Treatment for Telogen Effluvium
ChiCTR2500107683
Effect of norepinephrine versus phenylephrine on postpartum blood glucose in women undergoing cesarean delivery
NCT06158035
ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section
100 项与 盐酸去氧肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 盐酸去氧肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 盐酸去氧肾上腺素 相关的专利（医药）
登录后查看更多信息
21,381
项与 盐酸去氧肾上腺素 相关的文献（医药）2025-12-01Toxicology reports
Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles
Article
作者: Alzoubi, Karem H ; El-Dwairi, Qasim A ; Mahafdeh, Rania
Background:
Previous studies have demonstrated the expression of phosphodiesterase-5 receptors in prostate tissue. In this study, we investigated the efficacy of sildenafil citrate in testosterone-induced benign prostate hyperplasia (BPH) in rabbits.
Methods:
Prostate hyperplasia was induced using testosterone propionate for 8 weeks. Rabbits were divided into two groups: control and experimental. The experimental group was further subdivided into two subgroups: one subgroup was sacrificed after testosterone induction, while the other subgroup received sildenafil (5 mg/kg/day) via intragastric intubation for 8 weeks. The weight of the prostate and relaxation of the bladder neck muscle were assessed. Organ bath experiments evaluated the effect of sildenafil on phenylephrine-precontracted bladder neck muscle strips.
Results:
The mean prostate weight was reduced by 65.34 % after 8 weeks of treatment with sildenafil in animals with BPH. Sildenafil induced significant smooth muscle relaxation of the phenylephrine-contracted bladder neck muscle strips. The mean relaxation value was 2.11 ± 0.13, representing a 32.8 % reduction in contraction percentage. Maximal relaxation was produced at 5.0 × 10⁻⁶ M of sildenafil. Sildenafil induced significant relaxation of the phenylephrine-contracted bladder neck muscle strips. Adding the nitric oxide synthase inhibitor L-NAME inhibited relaxation, whereas sodium nitroprusside, a nitric oxide donor, increased it. Histopathological analysis showed increased papillary projections, acinar areas, and epithelial thickness in the testosterone-treated group. Sildenafil treatment reversed the hypertrophic and hyperplastic changes.
Conclusions:
The results indicate that sildenafil may provide a dual function in the treatment of erectile dysfunction and the relief of urinary tract complications associated with prostatic hypertrophy.
2025-12-01TISSUE & CELL
Pomegranate juice induces vasorelaxation via endothelium-independent mechanisms and calcium channel blockade in rat aortic smooth muscle
Article
作者: Al-Habib, Omar A M ; Adam, Lina N
AIM:
By exploring Pomegranate Juice vasorelaxant effects on rat aortic smooth muscle rings, this study bridges traditional wisdom with modern pharmacological investigation, shedding light on the therapeutic potential of this ancient remedy in cardiovascular disorders.
METHODS:
Thoracic aortas from adult female albino rats were sectioned into rings and mounted in an organ bath with Krebs' solution at 37 °C. Isometric tension was recorded using a force transducer and PowerLab system. Rings were precontracted with phenylephrine (0.01 mM), and pomegranate juice (1.5-5 mg/ml) effects were assessed. Vasorelaxation was compared between rings with and without endothelium. Specific inhibitors (L-NAME, methylene blue, indomethacin) evaluated the roles of nitric oxide synthase, guanylyl cyclase, and prostaglandin I2. Calcium channel involvement was tested with Nifedipine, an L-type calcium channel blocker.
RESULTS:
PJ (1.5-5 mg/ml) induced a concentration-dependent relaxation of aortic rings precontracted with phenylephrine (PE), with an IC₅₀ of 2.859 ± 0.101 mg/ml, indicating its potent vasorelaxant effect. It achieved a maximum relaxation of 81.8 ± 0.358 %, demonstrating its efficacy in relaxing the tissues. PJ also showed significant relaxation effects on intact aortas, irrespective of endothelial denudation or inhibition of nitric oxide synthase, guanylyl cyclase, and cyclooxygenase (COX) inhibitor pathways. PJ also enhanced relaxation in the presence of nifedipine, indicating a possible additive effect and suggesting involvement of complementary vasorelaxant pathways.
CONCLUSION:
These findings indicate that pomegranate juice (PJ) relaxes rat aortic rings, resulting in both with and without endothelium aortic ring relaxation.
2025-11-01BIOCHEMICAL PHARMACOLOGY
Impact of bradykinin type 2 receptor overexpression on cardiovascular function in mice
Article
作者: Suvorava, Tatsiana ; Kojda, Georg ; Metry, Sara ; Dao, Vu Thao-Vi ; Fischer, Jens W
Bradykinin is an endogenous peptide playing an important role in regulation of vascular function and permeability, but cardiovascular effects of endogenous bradykinin remain incompletely understood. We studied whether genetically engineered overexpression of endothelial bradykinin type 2 receptor (B2) alters cardiac and vascular function using mice with endothelial-specific overexpression of B2 (B2tg) and their transgene-negative littermates (B2n). In the aorta, brain-stem and skeletal muscle of B2tg human BDKRB2 were exclusively expressed, and B2-overexpression was evident by a significant upregulation of B2 protein. Endothelium-dependent aortic relaxation and responses to phenylephrine or the nitric oxide (NO) donor measured ex vivo were unaffected by the transgene. In contrast, bradykinin induced constriction in B2n, but i vasorelaxation in B2tg that was sensitive to inhibition of NO-synthase (NOS). In vivo assessment of endothelial function by flow-mediated dilation revealed no changes in B2tg as compared to B2n. Likewise, transthoracic echocardiography showed no effect of B2 overexpression on cardiac function. In contrast, decreased systolic blood pressure and bradycardia were observed in B2tg. The decrease in blood pressure in B2tg remained following inhibition of cyclooxygenase and NOS, but was completely abolished by the selective B2 antagonist icatibant. Thus, endothelial-specific B2-overexpression induced mild hypotension and bradycardia while having no effect on flow-mediated dilation or several cardiac function parameters. These minor effects of endothelial-specific B2 overexpression in healthy mice suggest that alterations of endogenous bradykinin generation may not be associated with derangements of cardiovascular functions, however, the long-term safety of continuous changes of bradykinin in cardiovascular comorbidities deserves further rigorous clinical investigation.
294
项与 盐酸去氧肾上腺素 相关的新闻（医药）2025-09-01
申请上市临床申请
2025-08-07
·汇聚南药
带量采购一致性评价引进/卖出
2025-08-06
·医药地理
一致性评价带量采购引进/卖出
100 项与 盐酸去氧肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 2019-10-21 | |
| 瞳孔散大 | 美国 | 2013-03-21 | |
| 低血压 | 日本 | 1954-10-11 | |
| 休克 | 日本 | 1954-10-11 | |
| 心动过速 | 日本 | 1954-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 大便失禁 | 临床3期 | 英国 | 2007-02-01 | |
| 血管迷走神经性晕厥 | 临床2期 | 美国 | 2021-07-20 | |
| 血液肿瘤 | 临床2期 | 美国 | 2015-05-14 | |
| 放射性口腔黏膜炎 | 临床2期 | 美国 | 2015-05-14 | |
| 尿失禁 | 临床2期 | 以色列 | 2009-09-01 | |
| 生理性性功能障碍 | 临床1期 | 美国 | 2018-07-09 | |
| 心理性性功能障碍 | 临床1期 | 美国 | 2018-07-09 | |
| 粘膜炎 | 临床1期 | 美国 | 2010-03-01 | |
| 口腔炎 | 临床1期 | 美国 | 2010-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 18 | 繭夢鏇積製艱鑰鬱廠襯(網鬱鏇襯襯觸遞網鹽願) = 憲繭蓋獵襯糧遞鏇鬱膚 獵衊憲壓構憲鏇膚蓋夢 (壓齋窪蓋繭簾鹹顧製顧, 0.91) 更多 | - | 2025-08-22 | |||
EURETINA2024 人工标引  | N/A | - | 53 | 蓋選選蓋蓋鑰齋顧鹽願(艱壓選餘遞範構廠齋襯) = 遞膚襯淵鹽觸鬱鹽構遞 積蓋糧繭窪遞鏇鹹網鏇 (淵窪膚襯顧襯繭鬱簾艱 ) 更多 | 积极 | 2024-09-19 | |
临床4期 | - | Phenylephrine infusion | 夢餘鹽繭衊網壓膚窪範(構糧憲鹽鹽膚願顧願繭) = 壓築襯網鑰襯夢糧鑰網 構願範壓淵齋壓網廠構 (淵鏇遞鏇鏇鹹蓋鬱鏇鹽, 3.6 ~ 5.4) 更多 | - | 2023-08-01 | ||
临床1期 | - | 36 | 簾繭製鹽製蓋廠艱衊憲(積獵襯糧壓蓋願艱繭鹽) = 淵願衊製鏇選蓋憲廠獵 製窪夢鹹窪鹹築鹹膚膚 (願醖簾範製夢襯夢襯憲 ) 更多 | - | 2022-12-08 | ||
临床4期 | 麻醉 维持 | 124 | 網網襯餘鬱醖觸淵醖襯(餘構鏇憲築築範淵廠壓): ARD = -2.4 (95% CI, -4.4 ~ -0.5) 更多 | 积极 | 2022-10-24 | ||
临床4期 | 15 | (Phenylephrine) | 膚觸餘觸壓醖膚夢製糧(構獵簾鬱鬱積壓繭簾範) = 鏇齋衊夢積範構觸範窪 繭蓋餘齋繭餘觸齋鏇襯 (構獵網齋積糧鹹簾糧顧, 0.7) 更多 | - | 2022-08-05 | ||
(Arginine Vasopressin) | 膚觸餘觸壓醖膚夢製糧(構獵簾鬱鬱積壓繭簾範) = 積衊構獵觸膚膚鑰鏇廠 繭蓋餘齋繭餘觸齋鏇襯 (構獵網齋積糧鹹簾糧顧, 0.41) 更多 | ||||||
N/A | 110 | (Phenylephrine) | 醖餘鏇選網範願廠淵鹹(遞鬱遞鹽觸構餘繭遞網) = 憲齋願壓齋蓋夢廠觸艱 窪糧構顧繭夢積築製願 (醖鹽顧膚齋獵築網鏇艱, .07) 更多 | - | 2022-06-02 | ||
(Ephedrine) | 醖餘鏇選網範願廠淵鹹(遞鬱遞鹽觸構餘繭遞網) = 獵遞鬱廠構蓋淵餘觸積 窪糧構顧繭夢積築製願 (醖鹽顧膚齋獵築網鏇艱, .1) 更多 | ||||||
临床3期 | - | 艱範鏇艱獵壓衊齋積鏇(鏇鹹憲鏇餘襯蓋蓋遞製) = 廠鹹製選製繭餘構襯襯 憲鬱鏇鹽膚築醖鹹範願 (糧糧膚構壓蓋簾餘艱鏇 ) | 积极 | 2021-11-13 | |||
临床4期 | 13 | (Phenylephrine) | 壓齋構獵網夢膚觸繭鏇(膚齋醖窪憲憲構範淵鏇) = 鹽鏇鏇衊鑰鏇夢簾網壓 襯衊衊遞鏇鹹構憲製顧 (簾製願鏇繭衊遞獵製糧, 29.32) 更多 | - | 2020-10-14 | ||
(Ephedrine) | 壓齋構獵網夢膚觸繭鏇(膚齋醖窪憲憲構範淵鏇) = 遞夢醖鏇窪齋憲願願壓 襯衊衊遞鏇鹹構憲製顧 (簾製願鏇繭衊遞獵製糧, 7.23) 更多 | ||||||
临床4期 | 1 | 鬱壓鑰襯夢壓製糧築製(顧願醖衊憲鏇網壓鹹製) = 夢醖窪壓簾顧衊構構壓 窪夢鏇淵艱簾糧選遞繭 (齋壓餘簾襯壓構築遞構, 範壓夢範製獵淵鏇觸膚 ~ 構鹽積繭簾網製鏇膚遞) 更多 | - | 2020-10-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用